• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

假性肢端肥大症-内分泌科的一个具有挑战性的实体:系统评价。

Pseudoacromegaly-A challenging entity in the endocrine clinic: A systematic review.

机构信息

Pituitary Tumor Unit, Endocrinology Department, Hospital CUF Descobertas, Lisbon, Portugal.

Faculdade de Medicina, Universidade Católica Portuguesa, Lisbon, Portugal.

出版信息

Clin Endocrinol (Oxf). 2024 Jun;100(6):542-557. doi: 10.1111/cen.15053. Epub 2024 Mar 28.

DOI:10.1111/cen.15053
PMID:38549284
Abstract

OBJECTIVE

Pseudoacromegaly encompasses conditions with features of acromegaly/gigantism, but no growth hormone (GH) or insulin-like growth factor-1 (IGF-1) excess. We aimed to review published pseudoacromegaly cases evaluated due to clinical suspicion of acromegaly.

DESIGN/PATIENTS: PubMed/Medline search was conducted to identify reported pseudoacromegaly cases, which were systematically reviewed to ensure they met eligibility criteria: (1) presentation suggestive of acromegaly; (2) acromegaly excluded based on normal GH, IGF-1 and/or GH suppression on oral glucose tolerance test (OGTT-GH); (3) diagnosis of the pseudoacromegaly condition was established. Data were retrieved from each case and analysed collectively.

RESULTS

Of 76 cases, 47 were males, mean ages at presentation and at first acromegaloid symptoms were 28 ± 16 and 17 ± 10 years, respectively. Most common conditions were pachydermoperiostosis (47%) and insulin-mediated pseudoacromegaly (IMP) (24%). Acromegaloid facies (75%) and acral enlargement (80%) were the most common features. Measurement of random GH was reported in 65%, IGF-1 in 79%, OGTT-GH in 51%. GH excess was more frequently excluded based on two tests (53%). Magnetic resonance imaging (MRI) was performed in 30 patients, with pituitary adenoma or hyperplasia being reported in eight and three patients, respectively. Investigations differed between cases managed by endocrine and non-endocrine specialists, the former requesting more often IGF-1, OGTT-GH and pituitary MRI.

CONCLUSIONS

Pseudoacromegaly is a challenging entity that may be encountered by endocrinologists. Pachydermoperiostosis and IMP are the conditions most often mimicking acromegaly. Adequate assessment of GH/IGF-1 is crucial to exclude acromegaly, which may be better performed by endocrinologists. Pituitary incidentalomas are common and require careful judgement to prevent unnecessary pituitary surgery.

摘要

目的

假性肢端肥大症包括具有肢端肥大症/巨人症特征但生长激素(GH)或胰岛素样生长因子-1(IGF-1)不超标的疾病。我们旨在综述因疑似肢端肥大症而接受评估的已发表的假性肢端肥大症病例。

设计/患者:通过 PubMed/Medline 搜索,确定报道的假性肢端肥大症病例,并对其进行系统回顾,以确保符合纳入标准:(1)有肢端肥大症表现;(2)根据口服葡萄糖耐量试验(OGTT-GH)时 GH、IGF-1 和/或 GH 抑制正常排除肢端肥大症;(3)确诊为假性肢端肥大症。从每个病例中检索数据并进行综合分析。

结果

76 例患者中,男性 47 例,就诊时和首次出现肢端肥大样症状时的平均年龄分别为 28±16 岁和 17±10 岁。最常见的疾病是厚皮骨膜病(47%)和胰岛素介导的假性肢端肥大症(IMP)(24%)。肢端肥大样面容(75%)和肢端增大(80%)是最常见的特征。65%的病例报告了随机 GH 测量值,79%报告了 IGF-1,51%报告了 OGTT-GH。GH 过多更常根据两项检查排除(53%)。30 例患者进行了磁共振成像(MRI)检查,分别有 8 例和 3 例报告发现垂体腺瘤或增生。内分泌和非内分泌专家管理的病例之间的检查存在差异,前者更常要求检查 IGF-1、OGTT-GH 和垂体 MRI。

结论

假性肢端肥大症是一种具有挑战性的疾病,内分泌科医生可能会遇到。厚皮骨膜病和 IMP 是最常模拟肢端肥大症的疾病。充分评估 GH/IGF-1 对于排除肢端肥大症至关重要,而内分泌科医生可能更擅长进行这种评估。垂体偶发瘤很常见,需要仔细判断以防止不必要的垂体手术。

相似文献

1
Pseudoacromegaly-A challenging entity in the endocrine clinic: A systematic review.假性肢端肥大症-内分泌科的一个具有挑战性的实体:系统评价。
Clin Endocrinol (Oxf). 2024 Jun;100(6):542-557. doi: 10.1111/cen.15053. Epub 2024 Mar 28.
2
Pseudoacromegaly.假性肢端肥大症。
Front Neuroendocrinol. 2019 Jan;52:113-143. doi: 10.1016/j.yfrne.2018.11.001. Epub 2018 Nov 15.
3
Pseudoacromegaly Associated with Non-Functioning Pituitary Adenoma.与无功能垂体腺瘤相关的假性肢端肥大症
Eur J Case Rep Intern Med. 2020 Oct 9;7(12):001950. doi: 10.12890/2020_001950. eCollection 2020.
4
Approach to the Patient With Pseudoacromegaly.假性肢端肥大症患者的处理方法。
J Clin Endocrinol Metab. 2022 May 17;107(6):1767-1788. doi: 10.1210/clinem/dgab789.
5
Insulin-mediated "pseudoacromegaly".胰岛素介导的“假性肢端肥大症”。
Hormones (Athens). 2011 Apr-Jun;10(2):156-61. doi: 10.14310/horm.2002.1306.
6
The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.口服葡萄糖耐量试验在166例肢端肥大症患者的诊断及治疗效果评估中的应用
J Clin Endocrinol Metab. 2009 Feb;94(2):523-7. doi: 10.1210/jc.2008-1371. Epub 2008 Nov 25.
7
Pachydermoperiostosis: a rare mimicker of acromegaly.厚皮性骨膜病:一种罕见的肢端肥大症模仿者。
Endocrinol Diabetes Metab Case Rep. 2017 May 16;2017. doi: 10.1530/EDM-17-0029. eCollection 2017.
8
Insulin resistance and pseudoacromegaly: A case report.胰岛素抵抗与假性肢端肥大症:一例报告
Diabetes Metab Syndr. 2019 Mar-Apr;13(2):901-903. doi: 10.1016/j.dsx.2018.12.009. Epub 2018 Dec 20.
9
Dynamic tests and basal values for defining active acromegaly.用于定义活动性肢端肥大症的动态试验和基础值
Neuroendocrinology. 2006;83(3-4):200-4. doi: 10.1159/000095528. Epub 2006 Oct 13.
10
Elevated IGF-1 with GH suppression after an oral glucose overload: incipient acromegaly or false-positive IGF-1?口服葡萄糖负荷后IGF-1升高伴生长激素抑制:早期肢端肥大症还是IGF-1假阳性?
Arch Endocrinol Metab. 2016 Nov-Dec;60(6):510-514. doi: 10.1590/2359-3997000000193. Epub 2016 Aug 25.